Program

Friday

  • Time
  • Topic/Speaker


  • 8:00 am – 8:30 am
  • Continental Breakfast in the Exhibit Hall
  • 8:30 am – 8:40 am
  • Welcome
    Sanjiv S. Agarwala, MD
    • Epidemiology and Early Detection

      Moderator: Ashfaq A. Marghoob, MD
  • 8:40 am – 8:45 am
  • Pretest
    Ashfaq A. Marghoob, MD
  • 8:45 am – 9:00 am
  • The Surgeon General’s Call to Action: Implications for Providers
    Speaker To Be Announced
  • 9:00 am – 9:20 am
  • Leveraging Technologies for Melanoma Screening and Diagnosis
    Ashfaq A. Marghoob, MD
  • 9:20 am – 9:35 am
  • The Current State of Automated Diagnosis in Europe
    Axel Hauschild, MD
  • 9:35 am – 9:50 am
  • Seeing the Future of Melanoma Detection through the Lens of Medical Informatics
    Steven Q. Wang, MD
  • 9:50 am – 10:05 am
  • Over Diagnosis of Cancer Screening: How Much is Too Much?
    Martin A. Weinstock, MD, PhD
  • 10:05 am – 10:15 am
  • Posttest and Panel Discussion
    Ashfaq A. Marghoob, MD
  • 10:15 am – 10:45 am
  • Break in the Exhibit Hall
    • Surgery

      Moderator: Vernon K. Sondak, MD
  • 10:45 am – 10:50 am
  • Pretest/Case
    Vernon K. Sondak, MD
  • 10:50 am – 11:05 am
  • MSLT-1 and MSLT-2: What Do They Tell Us?
    Charles M. Balch, MD, FACS
  • 11:05 am – 11:20 am
  • Is Completion Lymphadenectomy for Sentinel Node Positive Disease Obsolete?
    No: Merrick I. Ross, MD
    Yes: Daniel G. Coit, MD
  • 11:20 am – 11:40 am
  • Unanswered Questions: What is the Role of Sentinel Node Biopsy in Desmoplastic Melanoma?
    Dale Han, MD
  • 11:40 am – 11:45 am
  • Posttest and Perspective
    Vernon K. Sondak, MD
  • 11:45 am – 11:55 am
  • Break
    • Industry Expert Theater Lunch

      Sponsored by AMGEN
  • 11:55 am – 12:55 pm
  • Title To Be Announced
    This session is not approved for AMA PRA Category 1 Credit(s)™ and is neither provided by nor endorsed by HemOnc Today Melanoma 2015 or its accredited provider.
  • 12:55 pm – 1:00 pm
  • Break
    • Adjuvant Therapy

      Moderator: Sanjiv S. Agarwala, MD
  • 1:00 pm – 1:05 pm
  • Pretest/Case
    Sanjiv S. Agarwala, MD
  • 1:05 pm – 1:25 pm
  • Check-point Blockade as Adjuvant Therapy in Melanoma: Is It the Future?
    Alexander M.M. Eggermont, MD, PhD
  • 1:25 pm – 2:05 pm
  • How to Treat a High Risk Melanoma Patient with Adjuvant Therapy in 2015: A Case-based Round Table Discussion
    Alexander M.M. Eggermont, MD, PhD; Axel Hauschild, MD; Merrick I. Ross, MD; Vernon K. Sondak, MD
  • 2:05 pm – 2:15 pm
  • Posttest and Perspective
    Sanjiv S. Agarwala, MD
    • Local and Regional Therapy

      Moderator: Robert H.I. Andtbacka, MD, CM, FACS, FRCSC
  • 2:15 pm – 2:20 pm
  • Pretest/Case
  • Forum on Intralesional Therapy

  • 2:20 pm – 2:30 pm
  • Oncolytic Immunotherapy and Combinations
    Robert H.I. Andtbacka, MD, CM, FACS, FRCSC
  • 2:30 pm – 2:40 pm
  • PV-10 Chemoablation
    Sanjiv S. Agarwala, MD
  • 2:40 pm – 2:50 pm
  • Electroporation with IL-12
    Alain Algazi, MD
  • 2:50 pm – 3:00 pm
  • Panel Discussion: Where Do IL Therapies Fit in 2015?
    Sanjiv S. Agarwala, MD; Robert H.I. Andtbacka, MD, CM, FACS, FRCSC; Alain Algazi, MD
  • Local and Regional Therapy

  • 3:00 pm – 3:20 pm
  • Systemic Management of Brain Metastases
    Sanjiv S. Agarwala, MD
  • 3:20 pm – 3:30 pm
  • Posttest and Perspective
  • 3:30 pm – 4:00 pm
  • Break in the Exhibit Hall
    • Clinical Conundrum of the Year: Atypical Spitz Tumors

      Moderator: Vernon K. Sondak, MD
  • 4:00 pm – 4:05 pm
  • Pretest/Case
  • 4:05 pm – 4:25 pm
  • Atypical Spitz Tumors: Pathology Perspective
    Jane L. Messina, MD
  • 4:25 pm – 4:40 pm
  • Atypical Spitz Tumors: Surgical Management
    Vernon K. Sondak, MD
  • 4:40 pm – 4:55 pm
  • Atypical Spitz Tumors: Roundtable Discussion
    Charles M. Balch, MD, FACS; Alexander M.M. Eggermont, MD, PhD; Jane L. Messina, MD; Vernon K. Sondak, MD
  • 4:55 pm – 5:00 pm
  • Posttest and Perspective
    • Meet the Faculty Reception and Poster Presentations

  • 5:00 pm – 6:00 pm
  • Mingle with faculty and colleagues in the Exhibit Hall while you view the latest melanoma research conducted by fellow attendees.
    Not approved for AMA PRA Category 1 Credit(s)™.